公开(公告)号：US20240336689A1

公开(公告)日：2024-10-10

申请号：US18257528

申请日：2021-12-15

Applicant: MERUS N.V.

Inventor： Leonardo Andres SIRULNIK ,  Ernesto Isaac WASSERMAN

IPC: C07K16/28 ,  A61K9/00 ,  A61K9/08 ,  A61P35/00

CPC classification number: C07K16/2863 ,  A61K9/0014 ,  A61K9/08 ,  A61P35/00 ,  C07K16/28 ,  C07K2317/31

Abstract: The disclosure relates to means and methods in the treatment of cancer. The disclosure in particular relates to a method of treating a cancer in an individual with an antibody that binds LGR5 and EGFR. The invention further relates to the combination for use in such methods and to the combination for use in the manufacture of a medicament for the treatment of head and neck cancer.

公开(公告)号：US20220372166A1

公开(公告)日：2022-11-24

申请号：US17755196

申请日：2020-10-23

Applicant: Merus N.V.

Inventor： Ernesto Isaac WASSERMAN ,  Leonardo Andres SIRULNIK

IPC: C07K16/32 ,  A61P35/02

Abstract: The invention relates to a treatment using a bispecific antibody that comprises a first antigen-binding site that binds an extracellular part of ErbB-2 and a second antigen-binding site that binds an extracellular part of ErbB-3 for subjects that have cancer that has progressed after receiving a prior treatment. The prior treatment comprises a chemotherapy, a monospecific bivalent antibody comprising antigen-binding sites that bind an extracellular part of ErbB-2 or an extracellular part of ErbB-3, or a prior treatment with a tyrosine kinase inhibitor (TKI) of ErbB-2 or with a combination thereof.

公开(公告)号：US20240262912A1

公开(公告)日：2024-08-08

申请号：US18528535

申请日：2023-12-04

Applicant: Merus N.V.

Inventor： Alexander Berthold Hendrik BAKKER ,  Cornelis Jacob Johannes George BOL ,  Pieter Fokko VAN LOO ,  Leonardo Andres SIRULNIK ,  Ernesto Isaac WASSERMAN

IPC: C07K16/28 ,  A61K35/28 ,  A61K39/00 ,  A61P35/00

CPC classification number: C07K16/2809 ,  A61K35/28 ,  A61P35/00 ,  C07K16/2851 ,  A61K2039/545 ,  C07K2317/31 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2317/92

Abstract: The disclosure relates to means and methods of treating a subject for a CLEC12A positive cancer. In some embodiments the method comprises treating the subject in need thereof with two or more administrations of a bispecific antibody that binds CD3 and CLEC12A, wherein in a first administration an first amount of the bispecific antibody is administered and wherein in each of the subsequent administrations the amount of bispecific antibody is higher than the amount of bispecific antibody in the first administration. In some embodiments CLEC12A positive cancer treatment methods are provided at intervals and dosing regimens that spare hemopoietic stem cell compartment allowing for recovery of normal CLEC12A positive hemopoietic cells.

公开(公告)号：US20240052050A1

公开(公告)日：2024-02-15

申请号：US18257804

申请日：2021-12-03

Applicant: MERUS N.V.

Inventor： Pieter Fokko VAN LOO ,  Ernesto Isaac WASSERMAN ,  Cornelis Jacob Johannes George BOL ,  Gianluca LAUS ,  Leonardo Andres SIRULNIK

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/2878 ,  A61P35/00 ,  C07K16/2827 ,  C07K2317/31 ,  A61K2039/545

Abstract: The invention is relates to multispecific antibodies that comprise an antigen binding site that binds an extracellular part of CD137 and an antigen binding site that binds an extracellular part of a second membrane protein for use in a method of treatment of a cancer in a subject in need thereof. The invention further relates to such multispecific antibodies and methods and other aspects related thereto.